Life Sciences

FDA warns five companies for incomplete or false advertising

Pharma Compliance Alert, October 1, 2008

Shire, Johnson & Johnson, Novartis, Mallinckrodt, and Eli Lilly all received warning letters from the FDA about their marketing for attention deficit hyperactivity disorder (ADHD).

Post a Comment

Name:

 

E-mail:

 

Please enter your comment below:

   

Please enter the text below:

   
   

Most Popular